Richard M Stone - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Richard M Stone

Showing results (181-190 of 420) with videos related to

Pageof 42

Sort By:

Journal of Hematology & Oncology|July 7, 2021

Precision oncology in AML: validation of the prognostic value of the knowledge bank approach and suggestions for improvementMarius Bill, Krzysztof Mrózek, Brian Giacopelli, et al.

Blood|August 5, 2022

Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapyShivani Handa, Jeong-Ok Lee, Andriy Derkach, et al.

British Journal of Haematology|July 17, 2019

Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignanciesEllen Weisberg, Chengcheng Meng, Abigail E Case, et al.

Nature Medicine|December 13, 2006

Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformationTing Xi Liu, Michael W Becker, Jaroslav Jelinek, et al.

Leukemia|February 24, 2015

Pathological glycogenesis through glycogen synthase 1 and suppression of excessive AMP kinase activity in myeloid leukemia cellsHaymanti Bhanot, Mamatha M Reddy, Atsushi Nonami, et al.

American Journal of Hematology|December 6, 2019

Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re-induction chemotherapyJacqueline S Garcia, Shruti Bhatt, Geoffrey Fell, et al.

Haematologica|June 18, 2026

Dual CDK2 and CDK4/6 inhibition suppresses Rb/E2F signaling and enhances anti-leukemic activity in acute myeloid leukemiaEllen Weisberg, Basudev Chowdhury, Swati Garg, et al.

Leukemia|August 30, 2019

Clinical and molecular characterization of patients with acute myeloid leukemia and sole trisomies of chromosomes 4, 8, 11, 13 or 21Bhavana Bhatnagar, Ann-Kathrin Eisfeld, Jessica Kohlschmidt, et al.

Nature Genetics|March 17, 2009

A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasmsOuti Kilpivaara, Semanti Mukherjee, Alison M Schram, et al.

Blood Advances|September 29, 2021

t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve PDGFRA: relevance for imatinib insensitivitySarah B Mueller, Paola Dal Cin, Long P Le, et al.

Pageof 42

Search research articles

Showing results (181-190 of 420) with videos related to

Sort By:

Pageof 42

Journal of Hematology & Oncology|July 7, 2021

Precision oncology in AML: validation of the prognostic value of the knowledge bank approach and suggestions for improvementMarius Bill, Krzysztof Mrózek, Brian Giacopelli, et al.

Blood|August 5, 2022

Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapyShivani Handa, Jeong-Ok Lee, Andriy Derkach, et al.

British Journal of Haematology|July 17, 2019

Nature Medicine|December 13, 2006

Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformationTing Xi Liu, Michael W Becker, Jaroslav Jelinek, et al.

Leukemia|February 24, 2015

Pathological glycogenesis through glycogen synthase 1 and suppression of excessive AMP kinase activity in myeloid leukemia cellsHaymanti Bhanot, Mamatha M Reddy, Atsushi Nonami, et al.

American Journal of Hematology|December 6, 2019

Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re-induction chemotherapyJacqueline S Garcia, Shruti Bhatt, Geoffrey Fell, et al.

Haematologica|June 18, 2026

Dual CDK2 and CDK4/6 inhibition suppresses Rb/E2F signaling and enhances anti-leukemic activity in acute myeloid leukemiaEllen Weisberg, Basudev Chowdhury, Swati Garg, et al.

Leukemia|August 30, 2019

Clinical and molecular characterization of patients with acute myeloid leukemia and sole trisomies of chromosomes 4, 8, 11, 13 or 21Bhavana Bhatnagar, Ann-Kathrin Eisfeld, Jessica Kohlschmidt, et al.

Nature Genetics|March 17, 2009

A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasmsOuti Kilpivaara, Semanti Mukherjee, Alison M Schram, et al.

Blood Advances|September 29, 2021

t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve PDGFRA: relevance for imatinib insensitivitySarah B Mueller, Paola Dal Cin, Long P Le, et al.

Pageof 42